Results 171 to 180 of about 7,485,935 (361)
Molecular Oncology, EarlyView.We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu +10 more
wiley +1 more source
Review of: "Risk of death derived from Hazard Ratio should not be communicated as Relative Risk reductions for death in cancer clinical trials. Intentional or inadvertent?" [PDF]
, 2023 Ping Sun
openalex +1 more source
OPTIONAL UNIT POLICY IN CROP INSURANCE [PDF]
Utilizing ordered logit we examine the presence of two kinds of asymmetric information-adverse selection (intertemporal variability) and moral hazard (interspatial and/or residual variability) as revealed by the choice of optional units in Federal crop ...
Atwood, Joseph A., Shaik, Saleem
core +1 more source
Revisiting the hazards of hazard ratios through simulations and case studies
European Journal of EpidemiologyAbstract The hazard has been a central concept in the analysis and interpretation of time-to-event data for over 50 years. At any follow-up time, the hazard is the probability of the event happening in the next unit of time amongst those still at risk. Hazard ratios (HRs) between groups are frequently used to quantify the exposure/treatment’s
Michal Abrahamowicz +3 more
openaire +2 more sources
Subtleties in the interpretation of hazard ratios
, 2018 The hazard ratio is one of the most commonly reported measures of treatment effect in randomised trials, yet the source of much misinterpretation. This point was made clear by (Hernan, 2010) in commentary, which emphasised that the hazard ratio contrasts populations of treated and untreated individuals who survived a given period of time, populations ...
Martinussen, Torben +2 more
openaire +2 more sources
Molecular Oncology, EarlyView.Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena +15 more
wiley +1 more source
Moral hazard and bail-out in fiscal federations: evidence for the German Länder [PDF]
We identify investor moral hazard in the German fiscal federation. Our identification strategy is based on a variable, which was used by the German Federal Constitutional Court as an indicator to determine eligibility of two German states (Länder) to a ...
Heppke-Falk, Kirsten H. +1 more
core
Molecular Oncology, EarlyView.Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen +9 more
wiley +1 more source
Molecular cancer prevention: Intercepting disease
Molecular Oncology, EarlyView.Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco +2 more
wiley +1 more source
Molecular Oncology, EarlyView.Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source